Digital x-ray manufacturer Swissray and marketing partner Hitachi Medical Systems America received a multi-unit order for Swissray’s ddR systems from American Radiology Services of Baltimore. ARS, which is affiliated with Johns Hopkins Imaging, owns
Digital x-ray manufacturer Swissray and marketing partner Hitachi Medical Systems America received a multi-unit order for Swissrays ddR systems from American Radiology Services of Baltimore. ARS, which is affiliated with Johns Hopkins Imaging, owns and operates 18 imaging centers and provides professional services for 14 hospitals in the Baltimore area.
In other news, Swissray has added yet another division to its growing stable of international offices. Swissray Romania SRL, located in Bucharest, Romania, will function as a wholly owned subsidiary of Swissray and will oversee implementation of the $13.8 million order received by Swissray from the Romanian Ministry of Health last September (SCAN 10/27/99). That order covers 32 ddRMulti-Systems, and delivery is expected to begin in March. Swissray Romania will also be responsible for future sales, marketing, and service activities for Swissray products in that country.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.